about
Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesAnalysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionationFully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in miceDesign of targeted B cell killing agents.Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo.Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.Intravenous immunoglobulins--understanding properties and mechanisms.Advances in diagnosing and managing antibody-mediated rejection.Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.Intravenous immunoglobulin therapy in rheumatic diseases.Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation.Emerging drugs for the treatment of transplant rejection.Resolution of Hypoprothrombinemia-Lupus Anticoagulant Syndrome (HLAS) after multidrug therapy with rituximab: a case report and review of the literature.Polyvalent immunoglobulins: challenges and perspectivesThe expanding role of therapeutic antibodies.FcμR in human B cell subsets in primary selective IgM deficiency, and regulation of FcμR and production of natural IgM antibodies by IGIV.Infections in polymyositis and dermatomyositis: analysis of 192 cases.An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report.Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients
P2860
Q26864907-E1406905-9300-4F01-A975-F1E32A489145Q28728886-328F1F7F-D209-43E4-82A3-6D30848DC1C4Q33402880-F3FA8AD7-E58F-4E82-AEA0-6DD2A0BFA648Q33934041-C536E9F1-32DB-4273-874E-E326323C8CFAQ34258085-A815E755-5EB6-4C53-AE10-46F8EF8829BFQ34733689-9C2EFD8E-B52D-4DB0-8CFC-4DB5C27D3B3BQ36113220-8951DB7A-3BC4-434D-BE97-FE2A10872431Q37436638-FC6AEEB2-D61E-42BD-90B7-A3A8792F65A7Q37557375-3C1C90CC-0DE7-4FF9-B702-320CA77E8561Q37578120-772D0FDA-163F-4B18-84B8-D7C7F8447932Q37626118-968157B6-3B19-446D-87F4-5C9520D29618Q37676032-BB00FE5B-4BEA-45BE-989A-99FA6AA76AD8Q37861870-45681293-3BFC-4F72-A599-E77E0F480F3FQ37873722-DCD7C6A6-C377-4BEA-908A-3400FE1AE0AFQ37877263-A6ECBE29-4A79-41BB-AF72-6BC0FEBBE338Q37960177-BAACFF82-6A30-4403-8D11-23C775A2A89CQ38044488-DC3FB548-0BA7-49CA-8081-76B38C326C1EQ38170873-296F0DDE-61C1-4E13-8DCE-78DDC22FABE6Q38182645-8080B91A-3B16-4EE6-BA77-1D17BFF34A02Q39280258-B8B27A32-7A42-404C-B095-5D6373587AE4Q50046278-B076EFAD-1D53-479B-983E-4A6795F64872Q51428039-535F2ABC-49F7-49C1-803F-4F972F7BF51FQ58861212-2000FB34-1B0A-48A4-A2F8-A2B3C11A112D
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The antiinflammatory IgG.
@ast
The antiinflammatory IgG.
@en
type
label
The antiinflammatory IgG.
@ast
The antiinflammatory IgG.
@en
prefLabel
The antiinflammatory IgG.
@ast
The antiinflammatory IgG.
@en
P356
P1476
The antiinflammatory IgG.
@en
P2093
Srini V Kaveri
P304
P356
10.1056/NEJMCIBR0803649
P407
P577
2008-07-01T00:00:00Z